Literature DB >> 19274750

Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis.

Stephen H Caldwell1, Luiz Antonio R de Freitas, Sang H Park, Maria Lucia V Moreno, Jan A Redick, Christine A Davis, Barbee J Sisson, James T Patrie, Helma Cotrim, Curtis K Argo, Abdullah Al-Osaimi.   

Abstract

UNLABELLED: Mitochondrial dysfunction is an important element in the pathogenesis of nonalcoholic steatohepatitis (NASH). Intramitochondrial crystals (IMCs) are a well-documented morphological abnormality seen on transmission electron microscopy in this disease. It has been suggested that IMCs consist of phospholipids, but their exact composition remain uncertain many years after their discovery. Micellar phase transitions of phospholipid bilayers is a well-known but little-studied phenomenon in living systems. Its presence in the mitochondria of NASH would offer significant insight into the disease with possible therapeutic implications. We postulated that intramitochondrial disturbances in NASH are sufficient to produce such transitions and that their detection in fresh biopsies would therefore be a dynamic process. To test this, we performed a blinded, prospective analysis of fresh liver biopsy samples immediately fixed under different conditions. Quantitative transmission electron microscopy morphometry, performed by systematically counting total mitochondria and IMCs within areas of uniform dimension, showed a stepwise decline in IMCs with cooler fixation temperature in each subject studied. Randomization testing (Monte Carlo resampling) confirmed that the detection of IMCs was strongly dependent on fixation temperature (P < 0.0001).
CONCLUSION: These results indicate that the intramitochondrial crystals characteristic of NASH are highly dynamic and unstable structures. The findings offer the strongest support yet for their origin in micellar phase transitions. We speculate that such transitions result from microenvironmental changes within the mitochondria and carry therapeutic implications, especially in regard to dietary manipulations of mitochondrial lipid composition.

Entities:  

Mesh:

Year:  2009        PMID: 19274750     DOI: 10.1002/hep.22851

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

Review 1.  Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.

Authors:  Mohamed A Abdelmegeed; Seung-Kwon Ha; Youngshim Choi; Mohammed Akbar; Byoung-Joon Song
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  Impaired PI3K/Akt signal pathway and hepatocellular injury in high-fat fed rats.

Authors:  Ji-Wu Han; Xiao-Rong Zhan; Xin-Yu Li; Bing Xia; Yue-Ying Wang; Jing Zhang; Bao-Xin Li
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease.

Authors:  Denitra A Breuer; Maria Cristina Pacheco; M Kay Washington; Stephanie A Montgomery; Alyssa H Hasty; Arion J Kennedy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

4.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

5.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease.

Authors:  Nishanth E Sunny; Elizabeth J Parks; Jeffrey D Browning; Shawn C Burgess
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

6.  Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes.

Authors:  Manal F Abdelmalek; Mariana Lazo; Alena Horska; Susanne Bonekamp; Edward W Lipkin; Ashok Balasubramanyam; John P Bantle; Richard J Johnson; Anna Mae Diehl; Jeanne M Clark
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

8.  Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2013-09-10       Impact factor: 3.584

9.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

Review 10.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.